UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Current issues in the design and analysis of stepped wedge trials

Contemporary clinical trials, 2015-11, Vol.45 (Pt A), p.55-60

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Journal of hematology and oncology, 2016-12, Vol.9 (1), p.137-12, Article 137

2016

Link zum Volltext

Verfügbarkeit prüfen

Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium

JACC. Cardiovascular imaging, 2012-04, Vol.5 (4), p.358-366

2012

Link zum Volltext

Verfügbarkeit prüfen

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Journal of hepatology, 2022-03, Vol.76 (3), p.536-548

2022

Link zum Volltext

Verfügbarkeit prüfen

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

JAMA oncology, 2018-05, Vol.4 (5), p.652

2018

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Blood, 2015-04, Vol.125 (17), p.2649-2655

2015

Link zum Volltext

Verfügbarkeit prüfen

Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study

JACC. Cardiovascular imaging, 2012-04, Vol.5 (4), p.358-366

2012

Link zum Volltext

Verfügbarkeit prüfen

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Blood, 2018-11, Vol.132 (Supplement 1), p.4281-4281

2018

Link zum Volltext

Verfügbarkeit prüfen

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7067-7067

2016

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

Blood, 2015-12, Vol.126 (23), p.1609-1609

2015

Link zum Volltext

Verfügbarkeit prüfen

The Relevance of Different Methods of Calculating the Ankle-Brachial Index

American journal of epidemiology, 2010-02, Vol.171 (3), p.368-376

2010

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Blood, 2015-12, Vol.126 (23), p.58-58

2015

Link zum Volltext

Verfügbarkeit prüfen

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7065-7065

2016

Link zum Volltext

Verfügbarkeit prüfen

Earnings fraud: board control vs CEO control and corporate performance - 1992-2004: EARNINGS FRAUD: BOARD CONTROL VS CEO CONTROL

Managerial and decision economics, 2011-01, Vol.32 (1), p.17-34

2011

Link zum Volltext

Verfügbarkeit prüfen

The Relevance of Different Methods of Calculating the Ankle-Brachial Index The Multi-Ethnic Study of Atherosclerosis

American journal of epidemiology, 2010-02, Vol.171 (3), p.368-376

2010

Link zum Volltext

Verfügbarkeit prüfen

Earnings fraud: board control vs CEO control and corporate performance - 1992-2004

Managerial and decision economics, 2011-01, Vol.32 (1), p.17-34

2011

Link zum Volltext

Verfügbarkeit prüfen

Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium: The Multiethnic Study of Atherosclerosis (MESA)

JACC. Cardiovascular imaging, 2012-04, Vol.5 (4), p.358-366

2012

Link zum Volltext

Verfügbarkeit prüfen

Addressing Issues with the Stepped Wedge Design of Cluster-Randomized Clinical Trials

Granston, Tanya S

2013

Link zum Volltext
ProQuest

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(18)
Dissertationen
(1)

Sprache

Englisch
(19)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current issues in the design and analysis of stepped wedge trials

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial

Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

The Relevance of Different Methods of Calculating the Ankle-Brachial Index

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial

Earnings fraud: board control vs CEO control and corporate performance - 1992-2004: EARNINGS FRAUD: BOARD CONTROL VS CEO CONTROL

The Relevance of Different Methods of Calculating the Ankle-Brachial Index The Multi-Ethnic Study of Atherosclerosis

Earnings fraud: board control vs CEO control and corporate performance - 1992-2004

Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium: The Multiethnic Study of Atherosclerosis (MESA)

Addressing Issues with the Stepped Wedge Design of Cluster-Randomized Clinical Trials

Suchergebnisse filtern